Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans
Versicherungsschutz und Nutzungssteuerung für Medikamente bei Alkoholgebrauchsstörung in Medicaid Managed Care Plans
JAMA Network Open · 13.03.2025 · 8 (3) · e250695
DOI: 10.1001/jamanetworkopen.2025.0695 ↗Auf einen Blick
In 241 Medicaid Managed Care Plans wurde häufig mindestens ein Medikament gegen Alkoholgebrauchsstörung abgedeckt. Vor allem injizierbares Naltrexon unterlag jedoch häufiger Nutzungssteuerung.
Fragestellung
Wie ist die Abdeckung und Nutzungssteuerung von Acamprosat, Naltrexon und Disulfiram in Medicaid Managed Care Plans, und womit sind Unterschiede assoziiert?
Methode
Querschnittliche Inhaltsanalyse von Versicherungsdaten aus 2021 zu 241 umfassenden Medicaid MCPs; Auswertung mit Regressionsanalysen.
Ergebnisse
217/241 Pläne (90,0 %) deckten mindestens 1 Medikament ab. Abdeckung: Acamprosat 132 (54,7 %), orales Naltrexon 203 (84,2 %), injizierbares Naltrexon 175 (72,6 %), Disulfiram 152 (63,0 %), alle 4 Medikamente 103 (42,7 %).
Schlussfolgerung der Autor:innen
Die Autor:innen schließen, dass Bemühungen zur Ausweitung der Verordnung von AUD-Medikamenten durch Lücken im Versicherungsschutz begrenzt sein können. MCPs und Bundesstaaten können die Nutzung durch Abdeckung ohne Nutzungssteuerung unterstützen.
Kernaussagen
- 90,0 % der Pläne deckten mindestens 1 AUD-Medikament ab
- Injizierbares Naltrexon hatte am häufigsten Prior Authorization oder Mengenlimits
- Nur 42,7 % deckten alle 4 Medikamente ab
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 13.03.2025. Verfasst von Maureen T Stewart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts. Hauptthemen laut MEDLINE: Medicaid, Managed Care Programs, Alcoholism, Alcohol Deterrents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAAA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Evidence-based, patient-centered treatment for alcohol use disorder (AUD) can include pharmacotherapy with naltrexone, acamprosate, or disulfiram; however, these medications are rarely used. Medicaid managed care plans (MCPs) manage health services for nearly 80% of Medicaid enrollees and are the largest payer for addiction treatment services. Little is known about Medicaid MCP policies for AUD medications.
Objectives
To describe Medicaid MCPs’ coverage and management of acamprosate, naltrexone, and disulfiram for AUD and examine associations of plan characteristics and state policies with medication coverage. Design, Setting, and Participants In this cross-sectional study, a content analysis was performed of 2021 insurance benefit data for 241 comprehensive Medicaid MCPs in states using Medicaid managed care, as well as secondary sources. Data were analyzed from May to August 2024. Main Outcomes and Measures Medicaid MCP-reported medication coverage and utilization management requirements (eg, prior authorization, quantity limit requirements) for acamprosate, disulfiram, and oral and injectable naltrexone together and for each medication separately. Independent variables included plan characteristics (profit status, market share) and the state policy environment in which plans are embedded (Section 1115 substance use disorder waiver, state-defined preferred drug list). Regressions examined associations of plan characteristics and state policies with medication coverage.
Results
In this cross-sectional content analysis of 241 comprehensive Medicaid MCPs in 2021, 217 (90.0%) covered at least 1 medication for AUD: 132 (54.7%) covered acamprosate, 203 (84.2%) covered oral naltrexone, 175 (72.6%) covered injectable naltrexone, 152 (63.0%) covered disulfiram, and 103 (42.7%) covered all 4 medications. Prior authorization and quantity limits were rarely applied, except for injectable naltrexone, for which 75 plans (42.8%) imposed at least 1 of these utilization management requirements. Conclusions and Relevance This study suggests that efforts to expand AUD medication prescribing may be limited by gaps in health insurance coverage. Medicaid MCPs and states can support AUD medication utilization by covering these medications without applying utilization management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts.
- Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts.
- Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia.
- Booz Allen Hamilton Inc, McLean, Virginia.
- Department of Pharmacy Practice and Clinical Research, University of Rhode Island College of Pharmacy, Kingston.
Förderung
- NIDA NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Stewart, M. T., Feltus, S. R., Andrews, C. M., Acevedo, A., Thomas, C. P., Bratberg, J., Horgan, C. M., Hodgkin, D., & Adams, R. S. (2025). Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. JAMA Network Open, 8(3), e250695. https://doi.org/10.1001/jamanetworkopen.2025.0695
Vancouver
Stewart MT, Feltus SR, Andrews CM, Acevedo A, Thomas CP, Bratberg J, et al. Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. JAMA Network Open. 2025;8(3):e250695. doi:10.1001/jamanetworkopen.2025.0695
BibTeX
@article{Stewart2025,
author = {Stewart, Maureen T and Feltus, Sage R and Andrews, Christina M and Acevedo, Andrea and Thomas, Cindy Parks and Bratberg, Jeffrey and Horgan, Constance M and Hodgkin, Dominic and Adams, Rachel Sayko},
title = {Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {3},
pages = {e250695},
doi = {10.1001/jamanetworkopen.2025.0695}
}
EUVIMED